Vortioxetine Hydrobromide

氢溴酸伏硫西汀

Report date: 2025/03/24 14:42:58
NME

Base Information

Drug NameVortioxetine Hydrobromide
Drug Alias Name氢溴酸沃替西汀vortioxetinum氢溴酸沃赛汀vortioxetina伏硫西汀 +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1d (5-HT1d) receptor antagonistsSerotonin 1b (5-HT1b) receptor agonistsSerotonin transporter inhibitors +[6] 
TargetsSerotonin 7 (5-HT7) receptorSerotonin 1b (5-HT1b) receptorSerotonin 1a (5-HT1a) receptor +[6] 
Therapy Area/IndicationsAttention Deficit Disorder with HyperactivityDepressive Disorder, MajorDepressive Disorder +[17] 
Global Approved IndicationsDepressive Disorder, Major
Approved Indications in ChinaDepressive Disorder, Major
Original Approved Country/TerritoryUnited States
Original Approved Date2013/09/30
Country/TerritoryCzechiaBulgariaCanada +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of ZurichTakeda Pharmaceuticals USA IncLundbeck Llc +[11] 
Inactive CompaniesThe University Of ChicagoThomas Jefferson UniversitySun Yat-Sen University +[5] 
Active IndicationsDepressive Disorder, MajorDepressive DisorderAnxiety Disorders +[10] 
Inactive IndicationsAttention Deficit Disorder with HyperactivityBinge-Eating DisorderBipolar Disorder +[7] 

Other Information

ATC CodeN06AX26
Related LinksWikipediaDrugBankKEGG